Basilea Pharmaceutica Ltd (BSLN.SW) has updated its 2025 financial guidance, projecting higher total revenue following the recent in-licensing of a novel, oral, Phase 3-ready antibiotic.
The company expects that annual total revenue will increase by 8% to 225 million Swiss francs. It expects to maintain a high operating profit level of 50 million francs in 2025.
The company expects no material cash outflow related to income taxes as a result of the use of tax loss carry forwards, but a 10.7% income tax expense will be reflected in the 2025 net profit, in contrast to a 17.3 million francs one-time income tax benefit from releasing the deferred tax valuation allowance in 2024.
Basilea reported that its net profit for the first-half of 2025 declined to 15.8 million francs from 20.7 million francs last year. Earnings per share were 1.26 francs, down from 1.61 francs last year.
Total revenue for the first-half of 2025 104.0 million francs, an increase of 36.3% year-on-year.
For more earnings news, earnings calendar, and earnings for stocks, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.